Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
Buy
57
SRPT Quote, Financials, Valuation and Earnings
Last price:
$101.37
Seasonality move
:
18.62%
Day range:
$97.06 - $100.00
52-week range:
$97.06 - $173.25
Dividend yield:
0%
P/E ratio:
42.63x
P/S ratio:
5.70x
P/B ratio:
6.17x
Volume:
874.2K
Avg. volume:
955.2K
1-year change:
-21.47%
Market cap:
$9.4B
Revenue:
$1.9B
EPS (TTM):
$2.28
Analysts' Opinion
-
Consensus RatingSarepta Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 1 Hold rating, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $178.55, Sarepta Therapeutics has an estimated upside of 83.71% from its current price of $97.19.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $75.00 representing 22.83% downside risk from its current price of $97.19.
Fair Value
-
According to the consensus of 14 analysts, Sarepta Therapeutics has 83.71% upside to fair value with a price target of $178.55 per share.
SRPT vs. S&P 500
-
Over the past 5 trading days, Sarepta Therapeutics has underperformed the S&P 500 by -3.47% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Sarepta Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sarepta Therapeutics has grown year-over-year revenues for 29 quarters straight. In the most recent quarter Sarepta Therapeutics reported revenues of $658.4M.
Earnings Growth
-
Sarepta Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Sarepta Therapeutics reported earnings per share of $1.50.
Enterprise value:
9.2B
EV / Invested capital:
3.46x
Price / LTM sales:
5.70x
EV / EBIT:
33.00x
EV / Revenue:
4.84x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-26.12x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
29.07x
Gross Profit (TTM):
$1.6B
Return On Assets:
6.73%
Net Income Margin (TTM):
12.37%
Return On Equity:
20.83%
Return On Invested Capital:
10.04%
Operating Margin:
24.56%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $933M | $1.2B | $1.9B | $396.8M | $658.4M | |
| Gross Profit | $793M | $1.1B | $1.6B | $352.6M | $526.1M | |
| Operating Income | -$536.2M | -$267.8M | $218.1M | $24.6M | $161.7M | |
| EBITDA | -$594.9M | -$453.7M | $316.9M | $57M | $186.7M | |
| Diluted EPS | -$8.03 | -$5.83 | $2.28 | $0.76 | $1.50 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.5B | $2.6B | $2.6B | $2.6B | $3.1B | |
| Total Assets | $3B | $3.1B | $3.1B | $3.3B | $4B | |
| Current Liabilities | $416M | $452.7M | $619.6M | $653.7M | $731.7M | |
| Total Liabilities | $2.2B | $2.2B | $2.7B | $2.4B | $2.4B | |
| Total Equity | $761.8M | $928M | $385M | $859.3M | $1.5B | |
| Total Debt | $992.5M | $1.1B | $1.5B | $1.2B | $1.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$325.3M | -$501M | -$205.8M | -$54.7M | $92M | |
| Cash From Investing | -$1B | -$165.8M | $755.6M | -$64.4M | $764.1M | |
| Cash From Financing | $232.5M | $125M | $124.8M | $1.9M | $49M | |
| Free Cash Flow | -$357.6M | -$588.3M | -$352.7M | -$73.7M | $54M | |
SRPT
Sector
Market Cap
$9.4B
$37.4M
Price % of 52-Week High
56.1%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
-21.47%
-38.36%
Beta (5-Year)
0.794
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$101.92
200-day SMA
Sell
Level
$126.20
Bollinger Bands (100)
Sell
Level
108.68 - 127.08
Chaikin Money Flow
Sell
Level
-59.4M
20-day SMA
Sell
Level
$104.73
Relative Strength Index (RSI14)
Sell
Level
33.99
ADX Line
Sell
Level
29.26
Williams %R
Buy
Level
-98.9592
50-day SMA
Sell
Level
$112.88
MACD (12, 26)
Sell
Level
-3.83
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
404.4M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8366)
Sell
CA Score
(Annual)
Level (-0.6899)
Sell
Beneish M-Score
(Annual)
Level (-1.4539)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-2.1179)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Stock Forecast FAQ
In the current month, SRPT has received 12 Buy ratings 1 Hold ratings, and 1 Sell ratings. The SRPT average analyst price target in the past 3 months is $178.55.
-
Where Will Sarepta Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sarepta Therapeutics share price will rise to $178.55 per share over the next 12 months.
-
What Do Analysts Say About Sarepta Therapeutics?
Analysts are divided on their view about Sarepta Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sarepta Therapeutics is a Sell and believe this share price will drop from its current level to $75.00.
-
What Is Sarepta Therapeutics's Price Target?
The price target for Sarepta Therapeutics over the next 1-year time period is forecast to be $178.55 according to 14 Wall Street analysts, 12 of them rate the stock a Buy, 1 rates the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is SRPT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sarepta Therapeutics is a Buy. 12 of 14 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SRPT?
You can purchase shares of Sarepta Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sarepta Therapeutics shares.
-
What Is The Sarepta Therapeutics Share Price Today?
Sarepta Therapeutics was last trading at $101.37 per share. This represents the most recent stock quote for Sarepta Therapeutics. Yesterday, Sarepta Therapeutics closed at $97.19 per share.
-
How To Buy Sarepta Therapeutics Stock Online?
In order to purchase Sarepta Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Is Ford Stock Undervalued Amid the EV Transition?
There is a lot going on in the electric vehicle…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
49
SMTC alert for Mar 17
Semtech [SMTC] is down 0.49% over the past day.
Buy
62
PLPC alert for Mar 17
Preformed Line Products [PLPC] is up 3.8% over the past day.
Sell
50
NUTX alert for Mar 17
Nutex Health [NUTX] is up 4.82% over the past day.
